Huilai Zhang M.D.
Director

EDUCATION:

Degree-Granting Education:

1991.9-1996.7,  Bachelor, Medicine, Tianjin Medical University,

              Tianjin, P.R. China.

2000.9-2003.7,   Master, Oncology, Tianjin Medical University,

Tianjin, P.R. China.  

2003.9-2006.7,   M.D., Tianjin Medical University

Tianjin, P.R. China

EXPERIENCE

Academic Appointments:

1997.9-2001.12   Resident Doctor, Department of Medical Oncology,

Tianjin Medical University Cancer Hospital and Institute, Tianjin

2001.12-2009.12   Attending Doctor, Department of Medical Oncology,

Tianjin Medical University Cancer Hospital and Institute, Tianjin

2009.12-2017.12   Associate chief physician, Department of Medical Oncology, Tianjin Medical University Cancer Hospital and Institute, Tianjin

2017.12- Now    Chief physician, Department of Medical Oncology,

Tianjin Medical University Cancer Hospital and Institute, Tianjin

COMMITTEE MEMBERSHIPS:

2019.3-now, Vice chairman, Committee of Lymphoma Malignancies, Chinese Anti-cancer Association (CACA);

2018.1-now, Member of the standing committee, Anti-lymphoma Alliance, Chinese Society of Clinical Oncology (CSCO);

2018.12-now, Vice chairman, Committee of Lymphoma Malignancies, Chinese Aging Well Association;

2018.6-now, Vice chairman, Cancer Internal Medicine Branch, China Association for the Promotion of International Exchanges in Health Care

2016-now, Chairman, Committee of Lymphoma Malignancies, Tianjin Anti-cancer Association

2016-now, Chairman, the youth committee, Tianjin Anti-Aging Association

2014-now, Member of the youth committee, Committee of Clinical Cancer Chemotherapy, CACA

2014-now, Member of Committee of Hematological Malignancies, Tianjin Anti-cancer Association

2013-now, Member of Committee of Urologic Neoplasms, Tianjin Anti-cancer Association

2014-now, Member of Committee of Lymphoma Hematological Malignancies, China Elderly Oncology Association

 

HONORS AND AWARDS:

2003            The Third Prize of Tianjin Technology Progress Award, China 

The Basic and Clinical Study of the Improved Effect of Ginsenoside Rg3 for Immune Reconstitution After Autologous Peripheral Blood Stem Cell Transplantation

2005            The Excellent Paper Award of Livzon Fund, China,CSCO

The Clinical Study of the Improved Effect of Ginsenoside Rg3 for Immune Reconstitution After Autologous Peripheral Blood Stem Cell Transplantation

2006            The Second Prize of Tianjin Technology Progress Award, China

The Prospective Study on the Relapse of Patients with Malignant Lymphoma after Autologous Hematopoietic Stem Cell Transplantation.

2013     Young Investigator Award of the 22nd Asia Pacific Cancer Conference (APCC)

2016   The Third Prize of Tianjin Technology Progress Award, China

The clinical application and establishment of malignant lymphoma associated with venous thrombosis risk score model